You are here: Industry Insights > Pharma in China

Pharma in China

Has the booming PD-1 inhibitor reached its limit? Krebs Qin
October 18, 2024
In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.
Future Prospects of Small Molecule and Monoclonal Antibody Drugs in Oncology and Immunology Krebs Qin
October 18, 2024
Specifically, there is a balance between small molecules and monoclonal antibody drugs (mAbs) in the realm of oncology super blockbuster drugs, while immunology appears dominated by monoclonal antibodies and protein-based treatments.
What Sparks Will Come from the Collaboration Between CSPC and AstraZeneca? wan
October 18, 2024
On October 7, 2024, CSPC Pharmaceutical Group Co., Ltd entered into a significant collaboration agreement with AstraZeneca, creating quite a stir in the pharmaceutical industry.
Where Lies the Competitiveness of China's New Drugs for Central Nervous System? Prof. Zhang
October 18, 2024
The Global Challenges and Opportunities of the R&D of New Drugs for Central Nervous System
New Indication Approval for Ribociclib: A Game Changer for CDK4/6 Inhibitors Yefenghong
October 18, 2024
Recently, the FDA officially approved Novartis's ribociclib, in combination with aromatase inhibitors (AI), for the adjuvant treatment of hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC)
The Rapidly Expanding Global Weight Loss Market and the Role of Chinese Innovations PharmaSources/ChatGPT
August 28, 2024
The trend highlights China’s growing influence in the global pharmaceutical landscape and its increasing role in advancing global health solutions.
A Dark Horse in the Antibiotic World is Coming! Probably the Ultimate Weapon to Snipe Super-strong Bacteria Big Cat of Medical Field
July 03, 2024
On April 5, 2024, a new study from a Swedish university caused a stir in the scientific community.
Generic = Branded Drug, What are the Facts? Krebs Qin
July 03, 2024
It is no secret that the U.S. military does not trust the quality of generic drugs, and their disagreements and disagreements with the FDA over the quality control of generic drugs have long been made public.
Research Progress on Organoids and Microfluidics in Pharmaceutical Research and Development Wan
July 03, 2024
In recent years, there have been rapid technological advancements in the field of medical research, particularly in organ-on-a-chip and microfluidic technologies.
Which pharmaceutical giant is most willing to invest, and which excels at generating profits? Krebs Qin
May 27, 2024
The significance of R&D investment in biopharmaceutical companies cannot be overstated.